#United States #oncology #Yardley #Jubilant Therapeutics #Daniel O'Connor

Jubilant Therapeutics Inc. Welcomes New Leadership: Daniel J. O'Connor as President and CEO

On December 1, 2025, Jubilant Therapeutics Inc., a biopharmaceutical company in its clinical stages, confirmed the appointment of Daniel J. O'Connor as their new President and Chief Executive Officer. Known for his strong leadership in biotechnology and oncology, O'Connor brings a remarkable wealth of experience to the organization, which is dedicated to developing innovative therapies for oncology and autoimmune diseases.

A Proven Track Record in Biotechnology

Daniel O'Connor comes to Jubilant Therapeutics with more than 30 years of experience navigating the complexities of the biotech landscape. His previous role as CEO of Ambrx Biopharma saw significant advancements in company valuation, culminating in a successful acquisition. Before Ambrx, he played a crucial role at ImClone Systems, where he was instrumental in the clinical development and commercialization of a transformative oncology therapy, facing and overcoming significant intellectual property challenges along the way.

In another notable chapter of his career, O'Connor served as the CEO of Advaxis, a company focused on immune-oncology. He successfully transformed Advaxis into a late-stage clinical enterprise by securing substantial growth capital and fostering strategic partnerships with leading pharmaceutical companies.

The Future Looks Bright

Hari S. Bhartia, Chairman of Jubilant Therapeutics, expressed enthusiasm about O'Connor's appointment, stating, "We are delighted to welcome Dan as CEO of Jubilant Therapeutics Inc. His extensive experience in building and scaling biopharmaceutical enterprises, paired with his deep understanding of oncology and partnerships, will be pivotal in furthering our mission of delivering transformative therapies to patients in need."

O'Connor's vision for the company is equally optimistic. He remarked, "I am honored to lead Jubilant Therapeutics Inc., a company committed to pioneering breakthrough innovations in treating complex cancers. I look forward to collaborating closely with our talented team to drive progress, benefiting patients and our partners alike."

O'Connor's Background

In addition to his extensive professional experience, O'Connor holds a Juris Doctor (JD) from Penn State’s Dickinson Law, and he has proudly served in the U.S. Marine Corps. His multifaceted background equips him to navigate both the scientific and operational challenges inherent in the biopharmaceutical industry.

About Jubilant Therapeutics Inc.

Jubilant Therapeutics Inc. stands at the forefront of developing precision oral medicines aimed at addressing unmet medical needs in oncology and autoimmune diseases for genetically defined patient populations. Their state-of-the-art discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has shown promise through successful collaborations in the field.

The company boasts an exciting pipeline, which includes the first-in-class dual CoREST modifier, JBI-802, currently in Phase I/II trials for various tumors, and a novel brain-penetrant PRMT5 modulator, also in Phase I trials. Additionally, Jubilant is pursuing pre-clinical investigations into various other essential therapeutic targets, including PDL1 inhibitors and PAD4 inhibitors, highlighting their commitment to innovative drug development.

Headquartered in Pennsylvania, Jubilant Therapeutics Inc. continues to be guided by a cadre of globally renowned scientific advisors, all of whom align their vision with the mission to create novel solutions for pressing healthcare challenges. To stay updated with their progress, visit Jubilant Therapeutics or follow on Twitter @JubilantTx and LinkedIn.